Author

Vineet Sharma

Mass General BrighamPrimary ORCID profile (0009-0000-5630-6277 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Vineet SharmaiD1 paper · Indian Institute of Technology Bombay

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Amy M. Bertino· 1 shared Angelique Gilbert· 1 shared Claudia C. PastranaiD· 1 shared Kimmo PorkkaiD· 1 shared Matthew J. WalteriD· 1 shared Samuli EldforsiD· 1 shared Sridhar Nonavinkere SrivatsaniD· 1 shared Sumit RaiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Amy M. Bertino

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss

Samuli Eldfors, Sumit Rai, Vineet Sharma, Tareq Hossan, Claudia C. Pastrana, Amy M. Bertino, Angelique Gilbert, Sridhar Nonavinkere Srivatsan, Kimmo Porkka, Matthew J. Walter, Timothy Aaron Graubert

This study identifies SRSF2 and U2AF1 mutations as biomarkers of sensitivity to ATR-CHK1 pathway inhibitors and RUNX1 mutations as a mechanism of resistance in MDS/AML.

Leukemia · Oct 6, 2026Peer-reviewedCancer Biology